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Abstract
Rationale:Carney complex (CNC) is a multiple neoplasia syndrome with autosomal dominant inheritance. CNC is characterized by
the presence of myxomas, spotty skin pigmentation, and endocrine overactivity. No direct correlation has been established between
disease-causing mutations and phenotype.
Patient concerns: A 16-year-old boy was admitted because of excessive weight gain over 3 years and purple striae for 1 year.
Physical examination revealed Cushingoid features and spotty skin pigmentation on his face, lip, and sclera.
Diagnoses: The patient was diagnosed as Carney complex.
Interventions: the patient underwent right adrenalectomy and partial adrenalectomy of the left adrenal gland.
Outcome: Results of imaging showed bilateral adrenal nodular hyperplasia, multiple microcalcifications of the bilateral testes, and
compression fractureof the thoracolumbar spine.Histopathological results confirmedmultiple pigmentednodules in the adrenal glands.
DNA sequencing revealed a nonsense mutation in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A;
c.205C>T). After the second adrenalectomy, the Cushingoid features disappeared, and cortisol levels returned to normal.
Lessons: Carney complex is a rare disease that lacks consistent genotype–phenotype correlations. Our patient, who carried a
germline PRKAR1A nonsense mutation (c.205C>T), clinical features included spotty skin pigmentation, osteoporosis, and primary
pigmented nodular adrenal disease. Adrenalectomy is the preferred treatment for Cushing syndrome due to primary pigmented
nodular adrenal disease.
Abbreviations: ACTH= adrenocorticotropic hormone, CNC=Carney complex, IRB= institutional review board, LCCST= large-cell
calcifying Sertoli cell tumor, PKA= protein kinase A, PPNAD= primary pigmented nodular adrenal disease, RIa = 1-a regulatory subunit.
Keywords: adrenalectomy, Carney complex, Cushing syndrome, PRKAR1A, rare diseases
1. Introduction
Carney complex (CNC) is a multiple neoplasia syndrome with an
autosomal dominant inheritance.[1] The clinical manifestations of
CNC vary widely but may include myxomas of the heart, skin, and
other tissues and multiple other endocrine and nonendocrine
neoplasms including pituitary tumors, adrenocortical tumors,
thyroid neoplasms, psammomatous melanotic schwannomas,
testicular tumors, breast tumors, ovarian lesions, andbone lesions.[2]
More than 80% of CNC patients develop spotty skin pigmentation
or skin growths, which typically appear early in life and may be
located anywhere on the body, typically on the face, lips, genital
area, andmucosa.[3] Themost commonnoncutaneous lesions found
inCNCare cardiacmyxomas (affecting 20–40%of patients),which
are responsible for >50% of CNC-related mortality.[4–6]
CNC is a genetically heterogeneous disease, with >70%
patients with CNC carrying mutations of the PRKAR1A gene,[5]
which encodes the 1-a regulatory subunit (RIa) of the cAMP-
dependent protein kinase A (PKA) and functions as a tumor
suppressor gene.[7] Pathogenic PRKAR1A mutations include
single base substitutions, small (15bp) deletions/insertions,
combined rearrangements, and large deletions.[8–10] More than
125 PRKAR1A gene mutations have been identified; however,
linking genotype to phenotype has been challenging.[11] Although
previous studies [5,9,10,12–15] have demonstrated associations
between specific mutations and CNC manifestations, only 3
pathogenic variants (c.82C>T, c.491_492delTG, and c.709–
2_709–7 delATTTTT) have been identified in >3 unrelated
pedigrees.[5,7,13] The other mutations are unique (present in a
single kindred). To better understand genotype–phenotype
relationships in this rare heterogeneous disease, it is essential
to describe clinical features associated with specific mutations.
Here we present a case of CNC with a known germline
PRKAR1A nonsense mutation (c.205C>T) [5]; however, the
phenotype associated with this mutation has not yet been
established. Our results indicate that this PRKAR1A mutation
may be associated with increased pigmentation on the face, lip,
and sclera; osteoporosis resulting in compression fracture; and
primary pigmented nodular adrenal disease (PPNAD)-associated
Cushing syndrome.
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A 16-year-old boy was admitted to our department because of
excessive weight gain for 3 years and purple striate for 1 year. His
weight was 60kg, and height was 1.2 m. Physical examination
revealed typical Cushingoid features (moon face, buffalo hump,
central obesity, and purple striae of the bilateral axilla and lower
abdomen) (Fig. 1A), and spotty skin pigmentation on the face, lip,
and sclera (Fig. 1C–E). Laboratory findings revealed hyper-
cortisolism (Table 1). After low- and high-dose dexamethasone
suppression tests, cortisol levels were still high (462.9 and 828.3
Figure 1. Patient characteristics before and after adrenalectomies. (A) Cushingoid features include moon face, central obesity, and purple striae of the bilateral
axillary and lower abdomen before the operations. (B) Cushingoid features are decreased after left and right adrenalectomies. (C–E) Spotty skin pigmentation
(indicated by red arrows) on the face (C), lip (D), and sclera (E).
Table 1
Laboratory parameters of the patient.
Hormone (reference range) On admission After first adrenalectomy After second adrenalectomy
Cortisol 8, ng/mL (50–280 ng/mL) 310 318 56
Cortisol 16, ng/mL (20–140 ng/mL) 296 240 134
Cortisol 24, ng/mL (10–120 ng/mL) 259 351 74
ACTH 8, pg/mL (5.08–32.8 pg/mL) 5.88 12.6 8.57
ACTH 16, pg/mL (10.7–30.5 pg/mL) 10 14.72 6.32
ACTH 24, pg/mL (5–15 pg/mL) 5.51 6.69 7.72
Testosterone, ng/mL (1.75–7.81 ng/mL) 0.33 – –
Estradiol, pg/mL (20–47 ng/mL) <20 – –
Luteinizing hormone, mIU/mL (1.24–8.62 mIU/mL) 0.85 – –
Follicle-stimulating hormone, mIU/mL (1.27–19.26 mIU/mL) 0.74 – –
Prolactin, ng/mL (2.64–13.13 ng/mL) 13.61 – –
Growth hormone, mIU/L (0.5–13 mIU/L) 0.1 – –
ACTH = adrenocorticotropin.
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nmol/L, respectively), indicating adrenocorticotropic hormone
(ACTH)-independent Cushing syndrome. His grandparents have
no relevantdisease, andhis parentsdiedearlywithunknowncause.
Adrenal computed tomography showed bilateral adrenal
nodular hyperplasia (Fig. 2A and B). Ultrasonography showed
a normal thyroid but multiple microcalcifications of the bilateral
testes (Fig. 2C and D), suggesting large-cell calcifying Sertoli cell
tumor (LCCST). Considering the young age and the will of the
patient, the needle biopsy of the testes was not conducted to
confirm the LCCST. However, testicular ultrasound is conducted
every 6 month to monitor the lesions. Results of magnetic
resonance imaging showed a pituitary normal but a compression
fracture of the thoracolumbar spine (T5–T12 and L1).
Echocardiography did not reveal any cardiac myxomas.
On February 19, 2017, the patient underwent right adrenalec-
tomy via retroperitoneal laparoscopy; however, cortisol levels did
not normalize (Table 1). On March 1, 2017, the patient
underwent partial adrenalectomy of the left adrenal gland.
Histopathology findings of multiple pigmented nodules substan-
tiated the diagnosis of PPNAD (Fig. 2E). After the second
adrenalectomy, the Cushingoid features disappeared (Fig. 1B),
and cortisol levels returned to normal (Table 1).
2.1. Genetic analysis
Peripheral blood was collected after obtaining informed consent
from the patient’s grandparents. DNA was extracted from
leukocytes and amplified by the polymerase chain reaction.
Bidirectional DNA sequence analysis of the PRKAR1A gene
identified a known CNC-causing germline mutation (c.205C>T)
in exon 3 (Fig. 2F) and a second mutation (c.34 G>T) in the
intron preceding exon 9.
3. Discussion
In this study, we describe a patient with patient typical features of
CNC such as spotty skin pigmentation on the face, lip, and sclera;
osteoporosis resulting in compression fracture; and PPNAD-
associated Cushing syndrome. DNA sequencing identified a
known pathogenic mutation of PRKAR1A. Taken together, our
patient met the criteria for the diagnosis of CNC [2]: (1) spotty
pigmentation with the typical distribution (face, lip, and sclera);
(2) osteoporotic bone changes due primarily to glucocorticoid
excess, which accelerates bone resorption and decreases intestinal
calcium absorption and bone formation [16] (3); probable
LCCST, as demonstrated by ultrasonography of the bilateral
testes, which revealed multiple microcalcifications; and (4)
Cushing syndrome, which may be ACTH-dependent or
ACTH-independent (e.g., caused by PPNAD, as in our patient).
CNChasdiverse clinicalmanifestations,which typicallydevelop
over a period of years.[2]Mutations in PRKAR1A appear to be the
most common cause of CNC. Patients carrying PRKAR1A
mutations have more severe disease, with earlier presentation
and higher frequency of myxomas, thyroid, and gonadal tumors,
schwannomas, and lentigines compared withPRKAR1A-negative
patients.[5,17] In a small number ofPRKAR1Amissensemutations,
Figure 2. Results of imaging, histopathology, and DNA sequencing. Adrenal computed tomography scan showed bilateral adrenal nodular hyperplasia (A and B).
Ultrasonography demonstrated multiple microcalcifications of the bilateral testes (C and D). (E) Hematoxylin and eosin staining of the adrenal tissue revealedmultiple
pigmented nodules. (F) Sequencing of DNA extracted from peripheral leukocytes identified a heterozygous C>T substitution in PRKAR1A exon 3 (indicated by the
red arrow).
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themRNAescapesnonsense-mediateddecay, and theR I-amutant
proteins are associated with a more severe phenotype.[14,15] Two
PRKAR1A mutations (c.709–7del6 and M1V c.1A>G/p.M1V
substitution) are associatedwith low penetrance, early-life isolated
PPNAD, and Cushing syndrome.[18,19] However, in most cases,
genotype cannot predict phenotype or penetrance. Therefore, it is
necessary to describe clinical features associated with specific
mutations. According to our case presentation, the mutation (c.
205 C>T) in our case is inclined to cause pigmented spots,
osteoporosis, as well as PPNAD.
In conclusion, we have identified a reported PRKAR1A
nonsense mutation (c.205C>T) in a sporadic case of CNC
characterized by the spotty skin pigmentation, osteoporosis
resulting in compression fracture, and PPNAD-associated
Cushing syndrome. The description of clinical features of this
patient adds to our knowledge of CNC and PRKAR1A
mutations. The ability to recognize CNC is important for early
diagnosis and prevention of severe complications. PRKAR1A
mutation analysis should be conducted as soon as possible in
patients with suspected CNC.
3.1. Compliance with ethical standards
The institutional review board (IRB) of Daping Hospital of Third
Military Medical University waived IRB approval for the study.
Written informed consent was obtained from the patient for the
use of medical records and related images.
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